NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
YogaWorks, Inc. (NasdaqGM: YOGA) Class Period: Pursuant to the IPO commenced around August 10, 2017 and closed on August 16, 2017 Lead Plaintiff Deadline: February 25, 2019 Join the action: https://www.zlk.com/pslra-1/yogaworks-inc-loss-form?wire=3
The complaint alleges that Defendants violated their disclosure obligations because the Offering Materials materially misrepresented and failed to adequately disclose the truth concerning several known trends negatively impacting YogaWorks’ business at the time of the IPO, including, inter alia: (i) declining studio profitability; (ii) the impact of increased corporate overhead; (iii) declining financial metrics that would ultimately lead to a substantial impairment charge and (iv) the conditions that led the Defendants to postpone the initial offering.
To learn more about the YogaWorks, Inc. class action contact jlevi@levikorsinsky.com .
Immunomedics, Inc. (NASDAQ: IMMU) Class Period: August 23, 2018 - December 20, 2018 Lead Plaintiff Deadline: February 25, 2019 Join the action: https://www.zlk.com/pslra-1/immunomedics-inc-...orm?wire=3
The complaint alleges that, throughout the class period, defendants made false and misleading statements. The United States Food & Drug Administration issued citations against Immunomedics for multiple violations at its Morris Plains, New Jersey facility. The FDA citations included the manipulation of bioburden samples, backdating of records, and misrepresentation of integrity test procedures. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. On December 17, 2018, FDAnews.com published an article entitled “FDA Hits Immunomedics for Data Integrity Breach.” Upon this news, Immunomedics’ stock price fell sharply, damaging investors.
To learn more about the Immunomedics, Inc. class action contact jlevi@levikorsinsky.com .
Allergan plc (NYSE: AGN) Class Period: May 9, 2017 - December 19, 2018 Lead Plaintiff Deadline: February 19, 2019 Join the action: https://www.zlk.com/pslra-1/allergan-plc-loss-form?wire=3
During the Class Period, and unbeknownst to investors, Allergan misled investors regarding various “pharma and device approvals” and concealed the fact that the Company’s CE Mark for its textured breast implants and tissue expanders was expiring in Europe.
On December 19, 2018, the Company announced that, following a compulsory recall request from Agence Nationale de Sécurité du Médicament (“ANSM”), the French regulatory authority, the Company had suspended the sale of these products and that it was withdrawing all remaining supplies from European markets. The suspension of sales stemmed directly from the expiration of the company's CE Mark for these products, and the stock price fell drastically following the news.
To learn more about the Allergan plc class action contact jlevi@levikorsinsky.com .
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 55 Broadway, 10th Floor New York, NY 10006 jlevi@levikorsinsky.com Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
